Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Astellas Pharma’s $1.7B Iveric Bio buy aims to bolster its ophthalmology market position

By Brian Buntz | May 1, 2023

Astellas Pharma in the Drug Discovery & Development Pharma 50Astellas Pharma, the second largest Japanese pharma firm after Takeda, plans on scooping up the biopharma Iveric Bio for roughly $1.7 billion. Iveric focuses on discovering and developing novel therapies for retinal diseases, for approximately $1.7 billion.

Astellas believes the acquisition of Iveric Bio will strengthen its standing in the ophthalmology market, by adding the latter’s pipeline products to its portfolio. The companies expect the deal to close in the third quarter of 2023.

Zimura, a potential geographic atrophy breakthrough

The centerpiece of the Astellas-Iveric Bio deal is the drug candidate, Zimura (avacincaptad pegol), which is now in phase 3 clinical trials for geographic atrophy. The condition trails age-related macular degeneration (AMD) as a leading cause of irreversible blindness among the elderly. Geographic atrophy is an advanced form of the disease. No therapies are now approved to treat the condition.

Zimura, inhibitor of complement factor C5, has shown its potential in reducing the progression of geographic atrophy. If approved, Zimura would address a significant unmet medical need.

A closer look at the transaction

Astellas acquisition of Iveric Bio: Unaffected closing share price vs. purchase price

Astellas acquisition of Iveric Bio: Unaffected closing share price vs. purchase price

The bar graph on the right reflects financial figures related to Astellas’s purchase of Iveric Bio. The figures include the unaffected closing share price, purchase price and 30-day volume weighted average price (VWAP). The unaffected closing share price refers to the price of Iveric Bio’s shares at market close on the day prior to the acquisition announcement. Next, the purchase price reflects the premium amount Astellas has agreed to pay for each share of Iveric Bio.

Acquisition aligns with Astellas’ strategic focus on ophthalmology

The acquisition dovetails with Astellas Pharma’s strategic focus on expanding its presence in the ophthalmology market and ramping up its focus on retinal diseases in particular. The acquisition could Accelerate the commercialization of Zimura and other therapies for patients suffering from vision loss related to retinal diseases.

Moody’s sees the debt-funded transaction as credit positive for Astellas, given its impact on the company’s company’s drug pipeline and product portfolio. The deal will “likely materially increase Astellas’ leverage metrics,” wrote Dean Enjo, VP-Senior Analyst, Moody’s Japan. “The related increase in debt and leverage is a credit negative,” he added.

In its most recent credit opinion report on Astellas Pharma dated April 11, Moody’s gave Astellas an upper-medium grade credit rating of A3. The ratings firm cited the firm’s ability to generate free cash flow, given strong sales of its top-selling prostate cancer drug Xtandi (enzalutamide) and the successful launch of its antibody-drug conjugate Padcev (enfortumab vedotin).

Moody’s said in April that Moody’s credit rating was constrained by its “weakness in scale and product diversification compared to its peers.”  Moody’s noted in April that Astellas “derives over half of its revenue from three drugs”, leaving it vulnerable to sales dips or potential setbacks in its late-stage pipeline, which could thwart the ability to counteract future patent expirations.

The Iveric Bio acquisition could diversify Astellas’ concentrated drug portfolio with the addition of ACP, a drug for geographic atrophy, if the drug is approved by the US Food and Drug Administration later this year.”

Moody’s noted, however, that the company overall had a stable outlook, reflecting Moody’s expectation that it would maintain a strong business position in the global pharma industry.

Astellas’ Acquisition of Iveric Bio example of broader pharma M&A uptick

Astellas proposed acquisition of Iveric Bio is consistent with a recent trend of large pharmaceutical companies acquiring smaller biotech firms to expand their R&D capabilities and pipelines. Examples of notable acquisitions in 2023 include Merck’s purchase of Prometheus Biosciences in April for $10.8 billion, Pfizer’s acquisition of Seagen for $43.0 billion. Astellas proposed acquisition of Iveric Bio is consistent with a recent trend of large pharmaceutical companies acquiring smaller biotech firms to expand their R&D capabilities and pipelines. Examples of notable acquisitions in 2023 include Merck’s purchase of Prometheus Biosciences in April for $10.8 billion, Pfizer’s acquisition of Seagen for $43.0 billion. Other notable deals include Sanofi’s purchase of Provention Bio in March for $2.9 billion and Astellas’ acquisition of Iveric Bio in April for $5.9 billion.

M&A deals in 2023

M&A deals in 2023, from January to early May.


Filed Under: Drug Discovery and Development, Ophthalmology
Tagged With: Astellas Pharma, geographic atrophy, Iveric Bio, Ophthalmology, pharmaceutical M&A, retinal diseases, Zimura
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Collage of close-up male and female eyes isolated on colored neon backgorund. Multicolored stripes. Concept of equality, unification of all nations, ages and interests. Diversity and human rights
How a ‘rising tide’ of inclusivity is transforming clinical trials
Mary Marcus appointed CEO of NewAge Industries
DNA double helix transforming into bar graphs, blue and gold, crisp focus on each strand, scientific finance theme --ar 5:4 --personalize 3kebfev --v 6.1 Job ID: f40101e1-2e2f-4f40-8d57-2144add82b53
Biotech in 2025: Precision medicine, smarter investments, and more emphasis on RWD in clinical trials
Data analytics tools help doctors analyze trends in patient outcomes and population health.
External comparator studies: What researchers need to know to minimize bias
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE